Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.70 |
| ▸ | GSK3A | P49840 | 3/20 | 0.70 |
| ▸ | AURKA | O14965 | 6/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578690 | 0.90 | GSK3A (0.56) | GSK3BGSK3AAURKAPTK2JAK2 | |
| SCHEMBL1916423 | 0.88 | JAK3 (0.65) | GSK3BGSK3AAURKAPTK2JAK2 | |
| SCHEMBL4393743 | 0.87 | GSK3A (0.53) | GSK3BGSK3AAURKAPTK2JAK2 | |
| SCHEMBL11987614 | 0.86 | PTK2 (0.54) | GSK3BGSK3AAURKAPTK2JAK2 | |
| SCHEMBL1627996 | 0.86 | PTK2 (0.70) | PTK2JAK2JAK3 | |
| SCHEMBL1917337 | 0.83 | STK17A (0.60) | GSK3BGSK3AAURKAPTK2 | |
| SCHEMBL1916571 | 0.83 | GSK3A (0.56) | GSK3BGSK3AAURKAPTK2JAK2 | |
| SCHEMBL23087032 | 0.83 | PTK2 (0.60) | PTK2JAK2JAK3 | |
| SCHEMBL21565260 | 0.83 | PTK2 (0.57) | GSK3BGSK3APTK2JAK2JAK3 | |
| SCHEMBL28419527 | 0.83 | PTK2 (0.60) | PTK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | HINOVA PHARMACEUTICALS INC. (CN) | 2024-02-22 | — | — | US | disclosed |
| EP-4279488-A1 | SYNTHESIS METHOD FOR AMINOPYRIMIDINE FAK INHIBITOR COMPOUND | Hinova Pharmaceuticals Inc. (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367799-B1 | 2-AMINO-5-TRIFLUOROMETHYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS PTK2 KINASE INHIBITORS | IPHARMA H K LTD (HK) | 2018-08-01 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2483249-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| CN-101044137-A | 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-09-26 | — | — | CN | disclosed |
| EP-1781640-A1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006021544-A1 | 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | PTK2, PARP16, CDK6 | GSK3B 909/4885GSK3A 976/4885AURKA 609/4885 |
| US-20160362404-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | GSK3B 480/4885GSK3A 802/4885AURKA 3551/4885 |
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | GSK3B 1036/4885GSK3A 1259/4885AURKA 1005/4885 |
| US-20150376141-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | GSK3B 685/4885GSK3A 1061/4885AURKA 2987/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | GSK3B 242/4885GSK3A 346/4885AURKA 1/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | GSK3B 852/4885GSK3A 1044/4885AURKA 1385/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | GSK3B 176/4885GSK3A 248/4885AURKA 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.